The factors influencing the use of topical agents in combination with biologic therapies for the treatment of plaque psoriasis (PsO) are not well understood.
Objective:
To examine potential predictors of topical use in patients with moderate to severe plaque PsO receiving etanercept (ETN).
Methods:
Post hoc descriptive analyses and a multinomial regression of the REFINE study data were used to examine associations between topical agent potency and covariates, including Psoriasis Area and Severity Index (PASI) score, study site, and province.
Results:
Not achieving PASI 90 at week 12 predicted topical use, with a lower PASI 90 rate in patients who used high-potency topical agents post randomization (P = .003). Additionally, statistically significant differences were found in patterns of topical use among Canadian provinces (P = .007), with the use of high-potency topical agents being greater in Ontario and Quebec than the rest of Canada.
Conclusion:
This analysis revealed that region and PASI 90 status at week 12 predict topical use.
ParisiRSymmonsDPMGriffithsCEM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377-385.
2.
KurdSKGelfandJM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60:218-224.
KristensenMChuCQEedyDJ. Localization of tumour necrosis factor-alpha (TNF-α) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clin Exp Immunol. 1993;94:354-362.
5.
BannoTGazelABlumenbergM. Effects of tumor necrosis factor-α (TNF-α) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem. 2004;279:32633-32642.
TyringSGordonKBPoulinY. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719-726.
8.
KimballABRothmanKJKricorianG. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol. 2015;72:115-122.
9.
LeonardiCStroberBGottliebAB. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010;9:928-937.
10.
GottliebABLangleyRGStroberBE. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167:649-657.
11.
GuentherLC. Combination therapy of biologics with traditional agents in psoriasis. Skin Therapy Lett. 2011;16(6):1-3.
12.
StrohalRPuigLChouelaE. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat. 2013;24:169-178.
13.
Van de KerkhofPCMCambazardFHutchinsonPE. The effect of addition of calcipotriol ointment (50 µg/g) to acitretin therapy in psoriasis. Br J Dermatol. 1998;138:84-89.
14.
GrossmanRMThivoletJClaudyA. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol. 1994;31:68-74.
15.
CampioneEMazzottaAPaternòEJ. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients. Acta Derm Venereol. 2009;89:288-291.
16.
ThaçiDOrtonneJPChimentiS. A phase IIIb, multicenter, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163:402-411.
17.
KircikLH. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial. J Drugs Dermatol. 2011;10:878-882.
18.
LebwohlMGKircikLDuffinKC. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2013;69:385-392.
19.
RamsayCASchwartzBELowsonD. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatic combination treatment. Dermatology. 2000;200:17-24.
20.
SwinehartJMLoweNJ. UVABA therapy for psoriasis. J Am Acad Dermatol. 1991;24:594-597.
21.
PappKABarberKBissonnetteR. A Randomized, blinded assessor study to evaluate the efficacy and safety of etanercept 50 mg once weekly plus as needed topical agent vs. etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). J Eur Acad Dermatol Venereol. 2015;29:361-366.
22.
WanJAbuabaraKTroxelAB. Dermatologist preferences for first-line therapy of moderate-to-severe psoriasis in healthy adult patients. J Am Acad Dermatol. 2012;66:376-386.
